IXICO

Next week, we are at CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain from Oct 29th to Nov 1st! Here's a recap of our presence: Robin Wolz will present our latest findings with the Global Alzheimer's Platform Foundation on the Bio-Hermes Trial. 🕛Thursday, October 31st 2024 at 2:35pm in OC26 🧠 Oral Communication "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" If you're at CTAD, Bram Goorden and Roxanne Langlois will be with Robin to discuss and share imaging biomarker insights with the AD research community. Drop us a message if you're going so we can arrange a meeting! See you in Madrid!

Innovative trial recruitment strategies are crucial as it’s estimated that by 2050, 153 million people will live with dementia. Our deep-learning framework for clinical trial enrichment in Alzheimer’s Disease enhances trial enrichment using neuroimaging and clinical/demographic variables, designed to handle missing inputs effectively. 🧠 We utilized T1-MR and amyloid-PET images from major repositories and trained advanced neural networks and classifiers. This approach has shown promising results in identifying participants at early disease stages with accelerated decline. Our framework achieved high accuracy and can significantly reduce PET imaging costs. To learn more about our methods and results, download the full poster 📄https://lnkd.in/e9mRMRXW

In the ongoing quest to understand Alzheimer’s disease, recent studies have highlighted the importance of examining racial differences in amyloid PET imaging. Our latest research from the Global Alzheimer's Platform Foundation Bio-Hermes study compares amyloid positivity and global cortical SUVR between Black and White non-Hispanic participants, aiming to shed light on these critical differences. Key Points: Accurate Monitoring: This study is crucial for precisely tracking amyloid positivity and understanding its implications across different racial groups. 📊 Central Visual Read: Visual read was performed centrally using the VisQ process in MIM Software, considering visual inspection and global cortical area SUVR for classification into Aβ+ or Aβ-. 🧠💻 Variation Noted: A significantly higher variation between SUVR cut-off and visual read in Aβ- Black participants compared to White participants was noted, suggesting potential differences in amyloid uptake patterns. 🎯 This research represents a significant step forward in understanding racial differences in amyloid uptake, offering new insights for better patient care and more effective treatment strategies. Future work will focus on regional SUVR analysis to further explore these findings. 🌟🧠 Interested in learning more? 📄 Download our detailed poster here: https://lnkd.in/emPust9G

Recent advancements in MS research have led to the development of a fully automatic method for detecting and quantifying white matter lesions using deep learning. This method, developed by IXICO’s imaging and biomarker science team, is crucial for accurately tracking disease progression and evaluating treatment efficacy in Multiple Sclerosis. Key points include: Accurate Monitoring: This method is essential for precisely tracking how the disease progresses and assessing the effectiveness of treatments. 📊 Advanced Deep Learning Models: The approach leverages sophisticated models like VoxelMorph and LG-Net, which have been retrained on extensive MRI datasets. 🧠💻 High Accuracy: It outperforms traditional methods, precisely detecting and quantifying new lesions. 🎯 This advancement represents a significant step forward in MS research, offering new possibilities for better patient care and more effective treatment strategies. Presented at ECTRIMS 2024. 🌟🧠 Interested in learning more? 📄 Download our detailed poster on this method here: https://lnkd.in/ebWG9xSy

We're attending CTAD Clinical Trials on Alzheimer's Disease 2024 in Madrid, Spain from Oct 29th to Nov 1st! Robin Wolz will present our latest findings with Global Alzheimer's Platform Foundation on the Bio-Hermes Trial. 🕛Thursday, October 31st 2024 at 2:35pm in OC26 🧠 Oral Communication "A multi-stage approach to screen Amyloid status using plasma p-Tau217 prior to confirmatory Imaging applied to the Bio-Hermes Trial" Bram Goorden and Roxanne Langlois will be with Robin to discuss and share imaging biomarker insights with the AD research community. If you're going to CTAD, drop us a message to let us know you're going so we can arrange a meeting! See you in Madrid!

We’re #hiring a new Associate Image Analyst (6-month FTC) in Greater London, England. Apply today or share this post with your network.

This week, from September 18-20th, we will attend ECTRIMS in Copenhagen, Denmark! Here's a refresher of who's attending from IXICO: Kirsi Kinnunen will be presenting a poster on our latest work in understanding multiple sclerosis progression: 🕛 Poster Session 2 Session Date: Thursday, 19 September 2024 Session Time: 16.45 – 18.45 CEST 🧠 Poster P904 - Fully automatic detection and quantification of new white matter lesions using deep learning She will be at ECTRIMS to share imaging biomarker insights and learn from others in the MS clinical research field. Drop us a message if you're going to ECTRIMS! Maybe we can schedule a time to talk! See you in Copenhagen!

🔬 Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press 🧠 In the evolving landscape of Huntington’s disease (HD) clinical trials, there is a growing emphasis on precision and efficacy. Neuroimaging has emerged as a pivotal tool, offering unparalleled insights that enhance various aspects of trial design and execution. This comprehensive overview delves into the critical roles of structural, functional, and diffusion MRI, PET, MRS, and MEG in Huntington’s disease clinical trials. Key Highlights: ➡️Patient Selection: Enhancing precision in choosing trial participants. ➡️Safety Monitoring: Ensuring patient safety throughout the trial. ➡️Efficacy Demonstration: Proving the effectiveness of treatments. Challenges Addressed: ➡️Equipment requirements ➡️Standardization of procedures ➡️Managing patient burden ➡️Interpreting complex data This resource is invaluable for professionals involved in the design and execution of clinical trials, providing insights into effectively integrating neuroimaging methodologies. Special thanks to the authors: Nicola Hobbs, PhD, Marina Papoutsi, Aline Delva, Kirsi Kinnunen, Mitsuko Nakajima, Koen Van Laere, @Wim Vandenberghe, Priyantha Herath, and Rachael Scahill. Read more: https://lnkd.in/dhbzjg5Q

Next week, on September 12-14th, we will be at the European Huntington's Disease Network (EHDN) in Strasbourg, France! Marina Papoutsi will be presenting a poster on our latest work in understanding Huntington's disease progression: 🕛 September 12th - 12PM onwards 🧠 Poster E020 Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline Roxanne Langlois will be with Marina to share imaging biomarker insights and learn from others in the Huntington's disease clinical research field. Drop us a message if you're going to EHDN - We'd love to connect! See you in Strasbourg!

Next month, on September 18-20th, we will attend ECTRIMS in Copenhagen, Denmark! Kirsi Kinnunen will be presenting a poster on our latest work in understanding multiple sclerosis progression: 🕛 Poster Session 2 Session Date: Thursday, 19 September 2024 Session Time: 16.45 – 18.45 CEST 🧠 Poster P904 - Fully automatic detection and quantification of new white matter lesions using deep learning Kirsi will be at ECTRIMS to share imaging biomarker insights and learn from others in the MS clinical research field. So whether you're an old or new friend, stop by and say hello! Drop us a message if you're going to ECTRIMS! Maybe we can schedule a time to talk! See you in Copenhagen!